班夫 2022 年肾脏评论:思考与未来方向。

IF 5.3 2区 医学 Q1 IMMUNOLOGY Transplantation Pub Date : 2025-02-01 Epub Date: 2024-06-18 DOI:10.1097/TP.0000000000005112
Marion Rabant, Benjamin A Adam, Olivier Aubert, Georg A Böhmig, Marian Clahsen Van-Groningen, Lynn D Cornell, Aiko P J de Vries, Edmund Huang, Nicolas Kozakowski, Agnieszka Perkowska-Ptasinska, Leonardo V Riella, Ivy A Rosales, Carrie Schinstock, Naomi Simmonds, Olivier Thaunat, Michelle Willicombe
{"title":"班夫 2022 年肾脏评论:思考与未来方向。","authors":"Marion Rabant, Benjamin A Adam, Olivier Aubert, Georg A Böhmig, Marian Clahsen Van-Groningen, Lynn D Cornell, Aiko P J de Vries, Edmund Huang, Nicolas Kozakowski, Agnieszka Perkowska-Ptasinska, Leonardo V Riella, Ivy A Rosales, Carrie Schinstock, Naomi Simmonds, Olivier Thaunat, Michelle Willicombe","doi":"10.1097/TP.0000000000005112","DOIUrl":null,"url":null,"abstract":"<p><p>In September 2022, in Banff, Alberta, Canada, the XVIth Banff meeting, corresponding to the 30th anniversary of the Banff classification, was held, leading to 2 recent publications. Discussions at the Banff meeting focused on proposing improvements to the Banff process as a whole. In line with this, a unique opportunity was offered to a selected group of 16 representatives from the pathology and transplant nephrology community, experts in the field of kidney transplantation, to review these 2 Banff manuscripts. The aim was to provide an insightful commentary, to gauge any prospective influence the proposed changes may have, and to identify any potential areas for future enhancement within the Banff classification. The group expressed its satisfaction with the incorporation of 2 new entities, namely \"microvascular inflammation/injury donor-specific antibodies-negative and C4d negative\" and \"probable antibody-mediated rejection,\" into category 2. These changes expand the classification, facilitating the capture of more biopsies and providing an opportunity to explore the clinical implications of these lesions further. However, we found that the Banff classification remains complex, potentially hindering its widespread utilization, even if a degree of complexity may be unavoidable given the intricate pathophysiology of kidney allograft pathology. Addressing the histomorphologic diagnosis of chronic active T cell-mediated rejection (CA TCMR), potentially reconsidering a diagnostic-agnostic approach, as for category 2, to inflammation in interstitial fibrosis and tubular atrophy and chronic active T cell-mediated rejection was also an important objective. Furthermore, we felt a need for more evidence before molecular diagnostics could be routinely integrated and emphasized the need for clinical and histologic context determination and the substantiation of its clinical impact through rigorous clinical trials. Finally, our discussions stressed the ongoing necessity for multidisciplinary decision-making regarding patient care.</p>","PeriodicalId":23316,"journal":{"name":"Transplantation","volume":" ","pages":"292-299"},"PeriodicalIF":5.3000,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Banff 2022 Kidney Commentary: Reflections and Future Directions.\",\"authors\":\"Marion Rabant, Benjamin A Adam, Olivier Aubert, Georg A Böhmig, Marian Clahsen Van-Groningen, Lynn D Cornell, Aiko P J de Vries, Edmund Huang, Nicolas Kozakowski, Agnieszka Perkowska-Ptasinska, Leonardo V Riella, Ivy A Rosales, Carrie Schinstock, Naomi Simmonds, Olivier Thaunat, Michelle Willicombe\",\"doi\":\"10.1097/TP.0000000000005112\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>In September 2022, in Banff, Alberta, Canada, the XVIth Banff meeting, corresponding to the 30th anniversary of the Banff classification, was held, leading to 2 recent publications. Discussions at the Banff meeting focused on proposing improvements to the Banff process as a whole. In line with this, a unique opportunity was offered to a selected group of 16 representatives from the pathology and transplant nephrology community, experts in the field of kidney transplantation, to review these 2 Banff manuscripts. The aim was to provide an insightful commentary, to gauge any prospective influence the proposed changes may have, and to identify any potential areas for future enhancement within the Banff classification. The group expressed its satisfaction with the incorporation of 2 new entities, namely \\\"microvascular inflammation/injury donor-specific antibodies-negative and C4d negative\\\" and \\\"probable antibody-mediated rejection,\\\" into category 2. These changes expand the classification, facilitating the capture of more biopsies and providing an opportunity to explore the clinical implications of these lesions further. However, we found that the Banff classification remains complex, potentially hindering its widespread utilization, even if a degree of complexity may be unavoidable given the intricate pathophysiology of kidney allograft pathology. Addressing the histomorphologic diagnosis of chronic active T cell-mediated rejection (CA TCMR), potentially reconsidering a diagnostic-agnostic approach, as for category 2, to inflammation in interstitial fibrosis and tubular atrophy and chronic active T cell-mediated rejection was also an important objective. Furthermore, we felt a need for more evidence before molecular diagnostics could be routinely integrated and emphasized the need for clinical and histologic context determination and the substantiation of its clinical impact through rigorous clinical trials. Finally, our discussions stressed the ongoing necessity for multidisciplinary decision-making regarding patient care.</p>\",\"PeriodicalId\":23316,\"journal\":{\"name\":\"Transplantation\",\"volume\":\" \",\"pages\":\"292-299\"},\"PeriodicalIF\":5.3000,\"publicationDate\":\"2025-02-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Transplantation\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1097/TP.0000000000005112\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/6/18 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q1\",\"JCRName\":\"IMMUNOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Transplantation","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/TP.0000000000005112","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/6/18 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

2022 年 9 月,第十六届班夫会议在加拿大艾伯塔省班夫市举行,恰逢班夫分类法 30 周年纪念,会议产生了两本最新出版物。班夫会议的讨论重点是对整个班夫进程提出改进建议。为此,我们提供了一个独特的机会,让来自病理学和移植肾病学界的 16 位代表、肾移植领域的专家对这两份班夫手稿进行审阅。这样做的目的是提供有见地的评论,评估拟议的修改可能产生的预期影响,并确定班夫分类法未来可能改进的地方。专家组对将 "微血管炎症/损伤供体特异性抗体阴性和 C4d 阴性 "和 "可能由抗体介导的排斥反应 "这两个新实体纳入第 2 类表示满意。这些变化扩大了分类范围,有利于获取更多活检样本,并为进一步探讨这些病变的临床意义提供了机会。然而,我们发现班夫分类法仍然很复杂,可能会阻碍其广泛应用,尽管考虑到肾脏异体移植病理错综复杂的病理生理学,一定程度的复杂性可能是不可避免的。解决慢性活动性T细胞介导的排斥反应(CA TCMR)的组织形态学诊断问题、重新考虑间质纤维化和肾小管萎缩中的炎症以及慢性活动性T细胞介导的排斥反应的诊断方法(如第2类)也是一个重要目标。此外,我们认为在常规整合分子诊断之前需要更多的证据,并强调需要确定临床和组织学背景,并通过严格的临床试验证实其临床影响。最后,我们在讨论中强调了对患者护理进行多学科决策的持续必要性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Banff 2022 Kidney Commentary: Reflections and Future Directions.

In September 2022, in Banff, Alberta, Canada, the XVIth Banff meeting, corresponding to the 30th anniversary of the Banff classification, was held, leading to 2 recent publications. Discussions at the Banff meeting focused on proposing improvements to the Banff process as a whole. In line with this, a unique opportunity was offered to a selected group of 16 representatives from the pathology and transplant nephrology community, experts in the field of kidney transplantation, to review these 2 Banff manuscripts. The aim was to provide an insightful commentary, to gauge any prospective influence the proposed changes may have, and to identify any potential areas for future enhancement within the Banff classification. The group expressed its satisfaction with the incorporation of 2 new entities, namely "microvascular inflammation/injury donor-specific antibodies-negative and C4d negative" and "probable antibody-mediated rejection," into category 2. These changes expand the classification, facilitating the capture of more biopsies and providing an opportunity to explore the clinical implications of these lesions further. However, we found that the Banff classification remains complex, potentially hindering its widespread utilization, even if a degree of complexity may be unavoidable given the intricate pathophysiology of kidney allograft pathology. Addressing the histomorphologic diagnosis of chronic active T cell-mediated rejection (CA TCMR), potentially reconsidering a diagnostic-agnostic approach, as for category 2, to inflammation in interstitial fibrosis and tubular atrophy and chronic active T cell-mediated rejection was also an important objective. Furthermore, we felt a need for more evidence before molecular diagnostics could be routinely integrated and emphasized the need for clinical and histologic context determination and the substantiation of its clinical impact through rigorous clinical trials. Finally, our discussions stressed the ongoing necessity for multidisciplinary decision-making regarding patient care.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Transplantation
Transplantation 医学-免疫学
CiteScore
8.50
自引率
11.30%
发文量
1906
审稿时长
1 months
期刊介绍: The official journal of The Transplantation Society, and the International Liver Transplantation Society, Transplantation is published monthly and is the most cited and influential journal in the field, with more than 25,000 citations per year. Transplantation has been the trusted source for extensive and timely coverage of the most important advances in transplantation for over 50 years. The Editors and Editorial Board are an international group of research and clinical leaders that includes many pioneers of the field, representing a diverse range of areas of expertise. This capable editorial team provides thoughtful and thorough peer review, and delivers rapid, careful and insightful editorial evaluation of all manuscripts submitted to the journal. Transplantation is committed to rapid review and publication. The journal remains competitive with a time to first decision of fewer than 21 days. Transplantation was the first in the field to offer CME credit to its peer reviewers for reviews completed. The journal publishes original research articles in original clinical science and original basic science. Short reports bring attention to research at the forefront of the field. Other areas covered include cell therapy and islet transplantation, immunobiology and genomics, and xenotransplantation. ​
期刊最新文献
Kidney Transplant Outcomes in Amyloidosis: US National Database Study. Chronic Graft-versus-host Disease, Part 2: Clinical Success and Roadmap to the Future. The Aberrantly Expressed Nuclear Factor (Erythroid-derived 2)-Like 2 Participates in aGVHD by Modulating the Activation and Differentiation of CD4+ T Lymphocytes. Blood Gene Signature as a Biomarker for Subclinical Kidney Allograft Rejection: Where Are We? Organ Transplantation in India: NOT for the Common Good.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1